SCHEMBL183571

SCHEMBL183571

[N-]=[N+]=CC(=O)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8020164 0.78
SCHEMBL131344 0.75
SCHEMBL367403 0.67
SCHEMBL18920887 0.67 ALDH1A1 (0.32)
SCHEMBL13108979 0.65
SCHEMBL7998629 0.65
SCHEMBL43130 0.65
SCHEMBL28904420 0.65
SCHEMBL43175 0.63
SCHEMBL11370285 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2010508092-A 2010-03-18 JP claimed
EP-2077900-A2 METHODS AND SYSTEMS FOR IMMOBILIZING CORNEAL PROSTHESES SHIUEY, Yichieh (US) 2009-07-15 EP claimed
WO-2008055118-A2 METHODS AND SYSTEMS FOR IMMOBILIZING CORNEAL PROSTHESES SHIUEY YICHIEH (US) 2008-05-08 WO claimed
US-11951188-B2 Macrocyclic ligands with pendant chelating moieties and complexes thereof LUMIPHORE, INC. (US) 2024-04-09 US disclosed
US-20240067650-A1 MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF LUMIPHORE, INC. 2024-02-29 US disclosed
US-20240059668-A1 THIOHYDROXYPYRIDINE CHELATES LUMIPHORE, INC. 2024-02-22 US disclosed
EP-4232029-A1 THIOHYDROXYPYRIDINE CHELATES Lumiphore, Inc. (US) 2023-08-30 EP disclosed
WO-2023150540-A1 HYDROXAMIC ACID MACROCYCLIC AGENTS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF LUMIPHORE, INC. (US) 2023-08-10 WO disclosed
US-11691997-B2 Macrocycles LUMIPHORE, INC. (US) 2023-07-04 US disclosed
US-11603371-B2 Macrocyclic ligands with pendant chelating moieties and complexes thereof LUMIPHORE, INC. (US) 2023-03-14 US disclosed
WO-2022087317-A1 THIOHYDROXYPYRIDINE CHELATES LUMIPHORE, INC. (US) 2022-04-28 WO disclosed
US-20040082026-A1 Interferon alpha: remodeling and glycoconjugation of interferon alpha NEOSE TECHNOLOGIES, INC. 2004-04-29 US disclosed
US-20040077836-A1 Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF NEOSE TECHNOLOGIES, INC. 2004-04-22 US disclosed
US-20040063911-A1 Protein remodeling methods and proteins/peptides produced by the methods NEOSE TECHNOLOGIES, INC. 2004-04-01 US disclosed
US-20040043446-A1 Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A NEOSE TECHNOLOGIES, INC. 2004-03-04 US disclosed
US-20040001892-A1 Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-01-01 US disclosed
WO-2003031464-A2 REMODELING AND GLYCOCONJUGATION OF PEPTIDES NEOSE TECHNOLOGIES, INC. (US) 2003-04-17 WO disclosed
EP-1218413-A2 ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY The Regents of the University of California (US) 2002-07-03 EP disclosed
WO-2001022922-A2 ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-04-05 WO disclosed
US-5965106-A ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET PERIMMUNE HOLDINGS, INC. (US) 1999-10-12 US disclosed